Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab and Asciminib in Ph+ ALL
NCT06308588Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2024
- Primary completion
- May 2027
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, scFv Fragments
- Countries
- 1
01
Overview
A Phase 2 trial of asciminib in Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2024; status: recruiting.
02
Drugs
asciminib
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT06308588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06308588.